VOLITIONRX LTD
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
VNRX$0.20+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| $ | $ | |
| ASSETS · (UNAUDITED) | ||
| Current Assets | ||
| Cash and cash equivalents | 2,600,342 | 3,264,429 |
| Accounts receivable | 187,830 | 110,574 |
| Prepaid expenses | 250,061 | 338,660 |
| Other current assets | 255,769 | 343,145 |
| Total Current Assets | 3,294,002 | 4,056,808 |
| Property and equipment, net | 4,348,316 | 4,429,152 |
| Operating lease right-of-use assets | 560,610 | 599,816 |
| Intangible assets, net | 317,129 | 313,747 |
| Total Assets | 8,520,057 | 9,399,523 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
| Current Liabilities | ||
| Accounts payable | 3,011,897 | 2,766,178 |
| Accrued liabilities | 3,698,868 | 3,476,903 |
| Deferred revenue | 230,000 | 230,000 |
| Management and directors’ fees payable | 54,392 | 30,086 |
| Current portion of long-term debt | 862,475 | 860,223 |
| Current portion of finance lease liabilities | 49,179 | 46,737 |
| Current portion of operating lease liabilities | 224,690 | 221,755 |
| Current portion of grant repayable | 63,750 | 60,979 |
| Warrant liability | 77,848 | 97,886 |
| Total Current Liabilities | 8,273,099 | 7,790,747 |
| Deferred revenue, net of current portion | 22,663,400 | 22,663,400 |
| Long-term debt, net of current portion | 5,532,382 | 3,952,846 |
| Finance lease liabilities, net of current portion | 330,847 | 328,338 |
| Operating lease liabilities, net of current portion | 369,342 | 410,686 |
| Grant repayable, net of current portion | 377,662 | 361,242 |
| Total Long-Term Liabilities | 29,273,633 | 27,716,512 |
| Total Liabilities | 37,546,732 | 35,507,259 |
| Stockholders' Deficit | ||
| Common Stock | ||
| Authorized: 175,000,000 shares of common stock, at $0.001 par value per share | ||
| Issued and outstanding: 100,746,467 shares and 96,097,485 shares, respectively | 100,747 | 96,098 |
| Additional paid-in capital | 206,961,962 | 204,154,994 |
| Accumulated other comprehensive income | 131,702 | 385,631 |
| Accumulated deficit | (234,968,102) | (229,544,343) |
| Total VolitionRx limited Stockholders' Deficit | (27,773,691) | (24,907,620) |
| Non-controlling interest | (1,252,984) | (1,200,116) |
| Total Stockholders’ Deficit | (29,026,675) | (26,107,736) |
| Total Liabilities and Stockholders’ Deficit | 8,520,057 | 9,399,523 |
| (The accompanying notes are an integral part of these condensed consolidated financial statements) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.